Liquid parenteral products contain an overfill to ensure withdrawal of the declared volume. The overfill must be sufficiently high to compensate for the expected loss during product preparation and administration, but it should also be minimized to prevent accidental overdosing and unforeseen dose splitting of single-dose products. Finding the right balance between too much and too little overfill with an acceptable risk of product failure is challenging and requires consideration of the relevant sources of variability of the extractable volume. This article provides a novel approach for the calculation of the required overfill based on tolerance interval methodology. In a first step, a tolerance interval multiplier from the literature is proposed, and a simulation study is conducted to assess the appropriateness of its use for overfill determination. In a second step, this multiplier is adapted to cover operator-to-operator variability in the loss data and compared with other multipliers via a second simulation study. Use of a tolerance interval multiplier enables adaptation of the overfill such that the risk of not reaching the minimum extractable volume fulfills predefined acceptance criteria. By this, the scientific justification of the selected overfill is strengthened and control over a critical quality attribute is improved.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.5731/pdajpst.2022.012743 | DOI Listing |
Light Sci Appl
January 2025
Wuhan National Laboratory for Optoelectronics, Next Generation Internet Access National Engineering Laboratory, and Hubei Optics Valley Laboratory, School of Optical and Electronic Information, Huazhong University of Science and Technology, Wuhan, 430074, China.
We propose and validate a novel optical semantic transmission scheme using multimode fiber (MMF). By leveraging the frequency sensitivity of intermodal dispersion in MMFs, we achieve high-dimensional semantic encoding and decoding in the frequency domain. Our system maps symbols to 128 distinct frequencies spaced at 600 kHz intervals, demonstrating a seven-fold increase in capacity compared to conventional communication encoding.
View Article and Find Full Text PDFPediatr Neurol
January 2025
Department of Neurosurgery, Sanbo Brain Hospital, Capital Medical University, Beijing, China; Beijing Key Laboratory of Epilepsy, Beijing, China; Center of Epilepsy, Beijing Institute of Brain Disorders, Collaborative Innovation Center for Brain Disorders, Capital Medical University, Beijing, China. Electronic address:
Background: Sturge-Weber syndrome (SWS) is a rare congenital neurocutaneous disorder, often complicated by epilepsy. Approximately 50% of patients with SWS with epilepsy develop drug-resistant seizures, leaving limited treatment options. Vagus nerve stimulation (VNS) is a known therapy for refractory epilepsy, modulating neural activity to reduce seizures.
View Article and Find Full Text PDFClin Cancer Res
January 2025
UC San Diego Health System, La Jolla, United States.
Background: We evaluated the non-cyclic dinucleotide stimulator of interferon genes agonist MK-2118 ± pembrolizumab in patients with advanced solid tumors or lymphomas.
Methods: This first-in-human study (NCT03249792) enrolled patients with refractory, advanced solid tumors or lymphomas. Patients received intratumoral (IT) MK-2118 100-20,000 µg (arm 1), IT MK-2118 900-15,000 µg plus intravenous (IV) pembrolizumab 200 mg every 3 weeks (Q3W; arm 2), or subcutaneous (SC) MK-2118 5000-150,000 µg plus IV pembrolizumab 200 mg Q3W (arm 4); arm 3 (visceral injection of MK-2118) was not pursued.
Background And Objective: Intravesical instillation of chemotherapy (IIC) after radical surgery for upper urinary tract urothelial carcinoma (UTUC) reduces the risk of intravesical recurrence (IVR). However, compliance is low because of possible extravesical leakage after bladder cuff excision. The aim of this study was to evaluate the efficacy of preoperative IIC in reducing the risk of IVR.
View Article and Find Full Text PDFCancer Chemother Pharmacol
January 2025
Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
Background: ATR is an apical DDR kinase activated at damaged replication forks. Elimusertib is an oral ATR inhibitor and potentiates irinotecan in human colorectal cancer models.
Methods: To establish dose and tolerability of elimusertib with FOLFIRI, a Bayesian Optimal Interval trial design was pursued.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!